440 related articles for article (PubMed ID: 30198339)
1. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
[TBL] [Abstract][Full Text] [Related]
2. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
[TBL] [Abstract][Full Text] [Related]
3. Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements.
Morgan RA; Unti MJ; Aleshe B; Brown D; Osborne KS; Koziol C; Ayoub PG; Smith OB; O'Brien R; Tam C; Miyahira E; Ruiz M; Quintos JP; Senadheera S; Hollis RP; Kohn DB
Mol Ther; 2020 Jan; 28(1):328-340. PubMed ID: 31628051
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease.
Urbinati F; Wherley J; Geiger S; Fernandez BC; Kaufman ML; Cooper A; Romero Z; Marchioni F; Reeves L; Read E; Nowicki B; Grassman E; Viswanathan S; Wang X; Hollis RP; Kohn DB
Cytotherapy; 2017 Sep; 19(9):1096-1112. PubMed ID: 28733131
[TBL] [Abstract][Full Text] [Related]
6. Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders.
Uchida N; Hsieh MM; Raines L; Haro-Mora JJ; Demirci S; Bonifacino AC; Krouse AE; Metzger ME; Donahue RE; Tisdale JF
Nat Commun; 2019 Oct; 10(1):4479. PubMed ID: 31578323
[TBL] [Abstract][Full Text] [Related]
7. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
[TBL] [Abstract][Full Text] [Related]
8. Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy.
Baldwin K; Urbinati F; Romero Z; Campo-Fernandez B; Kaufman ML; Cooper AR; Masiuk K; Hollis RP; Kohn DB
Stem Cells; 2015 May; 33(5):1532-42. PubMed ID: 25588820
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease.
Poletti V; Urbinati F; Charrier S; Corre G; Hollis RP; Campo Fernandez B; Martin S; Rothe M; Schambach A; Kohn DB; Mavilio F
Mol Ther Methods Clin Dev; 2018 Dec; 11():167-179. PubMed ID: 30533448
[TBL] [Abstract][Full Text] [Related]
10. Correction of sickle cell disease in transgenic mouse models by gene therapy.
Pawliuk R; Westerman KA; Fabry ME; Payen E; Tighe R; Bouhassira EE; Acharya SA; Ellis J; London IM; Eaves CJ; Humphries RK; Beuzard Y; Nagel RL; Leboulch P
Science; 2001 Dec; 294(5550):2368-71. PubMed ID: 11743206
[TBL] [Abstract][Full Text] [Related]
11. A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice.
Wang X; McKillop WM; Dlugi TA; Faber ML; Alvarez-Argote J; Chambers CB; Wilber A; Medin JA
J Gene Med; 2024 Jan; 26(1):e3567. PubMed ID: 37455676
[TBL] [Abstract][Full Text] [Related]
12. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
Malik P; Arumugam PI; Yee JK; Puthenveetil G
Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by
Koniali L; Flouri C; Kostopoulou MI; Papaioannou NY; Papasavva PL; Naiisseh B; Stephanou C; Demetriadou A; Sitarou M; Christou S; Antoniou MN; Kleanthous M; Patsali P; Lederer CW
Cells; 2023 Dec; 12(24):. PubMed ID: 38132168
[TBL] [Abstract][Full Text] [Related]
14. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
15. Gene replacement therapy for sickle cell disease and other blood disorders.
Townes TM
Hematology Am Soc Hematol Educ Program; 2008; ():193-6. PubMed ID: 19074080
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
[TBL] [Abstract][Full Text] [Related]
17. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
18. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells.
Levasseur DN; Ryan TM; Pawlik KM; Townes TM
Blood; 2003 Dec; 102(13):4312-9. PubMed ID: 12933581
[TBL] [Abstract][Full Text] [Related]
19. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.
Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A
Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
Germino-Watnick P; Hinds M; Le A; Chu R; Liu X; Uchida N
Cells; 2022 Jun; 11(11):. PubMed ID: 35681538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
